



1405 Research Blvd, Suite 125
Rockville, MD 20850

VIA EDGAR

February 1, 2021

U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Mail Stop 4546
Washington, D.C. 20549

Attn: Ms. Laura Crotty
Mr. Tim Buchmiller
Ms. Christine Torney
Ms. Angela Connell

Re: **Sensei Biotherapeutics, Inc.**
Registration Statement on Form S-1
File No. 333-252138

Acceleration Request

Requested Date: Wednesday, February 3, 2021

Requested Time: 5:30 P.M. Eastern Time

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the "**Registrant**") hereby requests that the Securities and Exchange Commission (the "**Commission**") take appropriate action to cause the above-referenced Registration Statement on Form S-1 (File No. 333-252138) (the "**Registration Statement**") to become effective on February 3, 2021, at 5:30 p.m., Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff (the "**Staff**").

Once the Registration Statement has been declared effective, please orally confirm that event with Michael E. Tenta of Cooley LLP, counsel to the Registrant, at (650) 843-5636, or Mark Ballantyne of Cooley LLP at (703) 456-8084.

Very truly yours,

Sensei Biotherapeutics, Inc.

By: /s/ John Celebi

John Celebi
President and Chief Executive Officer

cc: Erin Colgan, Sensei Biotherapeutics, Inc.
Michael E. Tenta, Cooley LLP
Brian F. Leaf, Cooley LLP
Mark Ballantyne, Cooley LLP
Seo Salimi, Goodwin Procter LLP